Drug Interaction Report
3 potential interactions and/or warnings found for the following 2 drugs:
- nilotinib
- Ztalmy (ganaxolone)
Interactions between your drugs
nilotinib ganaxolone
Applies to: nilotinib, Ztalmy (ganaxolone)
Information for this minor interaction is available on the professional version.
Drug and food interactions
nilotinib food
Applies to: nilotinib
Do not consume grapefruit or grapefruit juice during treatment with nilotinib unless directed otherwise by your doctor. Grapefruit juice can increase the blood levels of nilotinib to dangerous levels, increasing the risk of an irregular heart rhythm that may be serious. You should seek immediate medical attention if you develop sudden dizziness, lightheadedness, fainting, shortness of breath, or heart palpitations during treatment with nilotinib. Food may also increase the blood levels of nilotinib. Therefore, you should take nilotinib on an empty stomach, meaning no food should be eaten for at least two hours before or one hour after taking nilotinib. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
ganaxolone food
Applies to: Ztalmy (ganaxolone)
Ganaxolone must be taken with food to ensure adequate absorption of the medication. It is best to avoid or limit the consumption of alcohol, as it can increase drowsiness or other nervous system side effects of ganaxolone. You should also avoid activities requiring mental alertness such as driving or operating hazardous machinery until you know how the medication affects you. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Gleevec
Gleevec is targeted cancer therapy for specific types of leukemia (blood cancer), bone marrow ...
Hydrea
Hydrea is used for chronic myelogenous leukemia, head and neck cancer
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Sprycel
Sprycel is used to treat chronic myeloid leukemia and acute lymphoblastic leukemia. Learn about ...
Cytoxan
Cytoxan is used for acute lymphocytic leukemia, acute nonlymphocytic leukemia, breast cancer ...
Tasigna
Tasigna (nilotinib) is used to treat Philadelphia chromosome positive chronic myeloid leukemia ...
Scemblix
Scemblix (asciminib) is an oral kinase inhibitor that may be used to treat adults with a type of ...
Bosulif
Bosulif is a kinase inhibitor that may be used to treat adults and some children aged 1 year and ...
Iclusig
Iclusig (ponatinib) used to treat a type of blood cancer called chronic myeloid leukemia (CML), or ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.